✦ LIBER ✦

Acute overdose of a new dopamine agonist, CV 205-502

✍ Scribed by Igor Tauveron; Jean-Michel Gesta; Isabelle Jalenques; Philippe Thiebiot

Book ID: 114719919
Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 268 KB
Volume: 40
Category: Article
ISSN: 0300-0664
DOI: 10.1111/j.1365-2265.1994.tb02498.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CV 205–502, a new dopamine agonist, vers

CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia

✍ van der Heijden, Pieter F.M.; de Wit, Willem; Brownell, Judith; Schoemaker, Joop 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 729 KB

CV205–502, A NEW NON-ERGOT DOPAMINE AGON

CV205–502, A NEW NON-ERGOT DOPAMINE AGONIST, REDUCES PROLACTINOMA SIZE IN MAN

✍ P. S. BARNETT; J. M. DAWSON; J. BUTLER; P. B. COSKERAN; J. J. MACCABE; A. M. McG 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 692 KB

Disappearance of a pituitary tumor after

Disappearance of a pituitary tumor after 15 months of treatment with CV 205–502, a new dopamine agonist

✍ Faβbender, W. J. ;Stracke, H. ;Bachmann, G. ;Rau, W. ;Federlin, K. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 482 KB

We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose o

Hormonal effects of CV 205–502, a novel

Hormonal effects of CV 205–502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties

✍ R.C. Gaillard; J. Brownell 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 471 KB

LONG-TERM TREATMENT WITH A NEW NON-ERGOT

LONG-TERM TREATMENT WITH A NEW NON-ERGOT LONG-ACTING DOPAMINE AGONIST, CV 205-502, IN WOMEN WITH HYPERPROLACTINAEMIA

✍ CARSTEN RASMUSSEN; TORBJÖRN BERGH; LEIF WIDE; JUDITH BROWNELL 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

Antiparkinsonian activity of a non-ergot

Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease

✍ Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,